Navigation Links
Battelle to Perform Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process
Date:10/28/2008

CAMBRIDGE, Mass. and COLUMBUS, Ohio, Oct. 28 /PRNewswire/ -- IntelligentMDx a developer and manufacturer of proprietary nucleic acid assays, today announced that it is working with the Battelle Eastern Science and Technology (BEST) Center to conduct assay performance verification studies of its nucleic acid-based diagnostic or 'smart' molecular diagnostic assays.

Under terms of the agreement Battelle will perform various testing of IntelligentMDx's Quantitative BK Virus (BKV) Real-Time PCR Assay to identify its performance characteristics. Financial terms of the agreement were not disclosed.

BKV has recently emerged as an important pathogen in nephropathy in kidney transplant patients and hemorrhagic cystitis in human stem cell transplant patients. The IntelligentMDx Quantitative BK Virus Real-Time PCR Assay can be utilized to track the course of infection and monitor response to treatment.

The biggest hurdle for a nucleic acid testing is that current reagent design methods do not specifically address the core set of challenge affecting reagent performance -- such as genetic diversity and other key performance metrics. IntelligentMDx has a proprietary process to manage the design, development and manufacturing of pathogen assays that are platform agnostic and adaptable to all nucleic acid detection methodologies. The IntelligentMDx process allows for rapid time to market.

About IntelligentMDx

IntelligentMDx(TM) develops and manufactures tests, under regulatory compliance, for a broad range of molecular based systems for use in clinical molecular diagnostics, drug development and applied science applications. Our mission is to rapidly translate the needs of the clinician, patient and partners into very specific, highly sensitive, robust clinically impactful tests, thus enabling caregivers worldwide to provide care with certainty(SM).

IntelligentMDx's competitive advantage incorporates intelligent software with assay development and manufacturing expertise within a Quality System compliant with both ISO and FDA current regulations. Our uniquely integrated modular test development process provides clinically impactful and novel nucleic-acid testing solutions including Real-Time PCR assays. The company is working to use its proprietary "symptom-based diagnostics" approach for disease detection. Our goal is to provide the end users with "smart" tests that detect several related diseases at once -- more quickly and more economically than current standard individual tests. The quality and breadth of our product candidate pipeline, platform-agnostic approach, scientific team and strategic collaborations and partnerships is enabling us to become a fully integrated molecular diagnostics company.

About Battelle

Battelle's Global Health and Life Sciences business delivers a comprehensive set of R&D services to solve complex challenges for government health agencies and medical device, biotechnology, and pharmaceutical firms. Including the national laboratories it manages or co-manages, Battelle oversees over $200 million annually in health and life sciences-research contributing to advances in medical devices, pharmaceuticals, public health, and next-generation diagnostics and therapeutics.

Battelle is the world's largest non-profit independent research and development organization, providing innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management, National Security, Energy Technology, and Health and Life Sciences. It advances scientific discovery and application by conducting $4 billion in global R&D annually through contract research, laboratory management and technology commercialization. Headquartered in Columbus, Ohio, Battelle oversees 20,400 employees in more than 120 locations worldwide, including six national laboratories which Battelle manages or co-manages for the U.S. Department of Energy.

Statements in this release, including those that may relate to revenue growth, trends in financial or operational performance, litigation, new product plans and business prospects are forward-looking statements. Actual results might differ materially from these statements due to risks and uncertainties, including the impact of competitive products and pricing, market acceptance of new products, market conditions and enforcement of intellectual property rights. A more detailed description of these risks and other risks applicable to IntelligentMDx are available upon request from IntelligentMDx. IntelligentMDx disclaims any intent or obligation to update these forward-looking statements.

CONTACT: For more information on IntelligentMDx, visit http://www.IntelligentMD.com or contact Corporate Communications, cc@IntelligentMD.com, 617-871-6400.

For more information on Battelle, visit http://www.battelle.org or contact Public Relations Manager Katy Delaney at (410) 306-8638 or at delaneyk@battelle.org.


'/>"/>
SOURCE IntelligentMDx
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Battelle and YuYu Pharma Create the First Joint Bioequivalence Test Experimentation Institution
2. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
5. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
6. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
7. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
8. Physician Team at Northwestern Memorial Performs Rare Oral Gallbladder Removal
9. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
10. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
11. New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... ... "Color Grading media can be time consuming but with FCPX LUT Night ... Austin - CEO of Pixel Film Studios. , With the FCPX LUT Night ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ...
(Date:5/27/2016)... CA (PRWEB) , ... May 27, 2016 , ... More ... Health, so it is not surprising that bariatric surgery has received increased attention in ... Journal explains. Of course, when it comes to weight loss, most people are familiar ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and ... to shed lights on the variety of topics detailing why we appreciate nurses in ... why this career has gone from being in a major recession to one of ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... educate the many who are unaware of the plight of aphasia. In collaboration ... within the “Stroke Awareness” campaign. , The link between stroke and aphasia is ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year Standard ... Allison Outerbridge is this year’s Life University winner of a $2,500 ... university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter at ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... May 26, 2016 Since its ... into an essential life science tool for conducting genetic ... BCC Research reveals in its new report that the ... phase, one powered by a range of new applications ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... Frankfurt Prime Standard: QIA) today announced that the company has ... GmbH to develop and commercialize predictive assays in oncology. An ... a marker to predict effectiveness of anthracycline treatment in triple ... are pleased to partner with Therawis, which developed the PITX2 ...
(Date:5/25/2016)... 2016 As illustrated by the ... month, the numbers and momentum of cannabis in the ... the billions, more research and development push the sector ... of Legal Marijuana Markets Report  from from ArcView Market ... of the increase in sector is attributed to adult ...
Breaking Medicine Technology: